CAR T-Cell Benefit in Lenalidomide-Refractory Myeloma CAR T-Cell Benefit in Lenalidomide-Refractory Myeloma

The CAR T-cell construct was associated with significantly better progression-free survival than standard-of-care multidrug regimens.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news